177Lu-DOTATATE

You have access
Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of ¹⁷⁷Lu-DOTATATE PRRT: Does In Vivo Molecular PET Perform Better from the Viewpoint of Prediction of Tumor Biology?
Aadil Adnan and Sandip Basu

Journal of Nuclear Medicine Technology September 1, 2022, 50 (3) 248-255; DOI: https://doi.org/10.2967/jnmt.121.261998
You have access
Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After ¹⁷⁷Lu-DOTATATE Infusion
Sameer Tipnis, William J. Rieter, Vladimir Henderson-Suite and Leonie Gordon

Journal of Nuclear Medicine Technology September 1, 2022, 50 (3) 274-277; DOI: https://doi.org/10.2967/jnmt.121.262820
You have access
Practical Considerations for Implementation of ¹⁷⁷Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Diane K. Soulek, Molly E. Martin, Nic J. Mastascusa and Stephen A. Graves

Journal of Nuclear Medicine Technology September 1, 2022, 50 (3) 195-202; DOI: https://doi.org/10.2967/jnmt.122.263813
You have access
Combined ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy and Platinum-Based Chemotherapy in Recurrent, Metastatic Sinonasal Neuroendocrine Carcinoma: A Promising Therapeutic Option
Aadil Adnan and Sandip Basu

Journal of Nuclear Medicine Technology September 1, 2020, 48 (3) 292-294; DOI: https://doi.org/10.2967/jnmt.119.237354
You have access
Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with ¹⁷⁷Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy
Aadil Adnan and Sandip Basu

Journal of Nuclear Medicine Technology March 1, 2020, 48 (1) 36-39; DOI: https://doi.org/10.2967/jnmt.119.227058
You have access
Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of ⁶⁸Ga/¹⁷⁷Lu-DOTATATE with Improvement of Vision
Rahul V. Parghane and Sandip Basu

Journal of Nuclear Medicine Technology June 1, 2019, 47 (2) 171-172; DOI: https://doi.org/10.2967/jnmt.118.217455
You have access
Guidance on ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
Amanda Abbott, Christopher G. Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly Boyle, Matthew H. Kulke, Jennifer A. Chan, Heather A. Jacene and Annick D. Van den Abbeele

Journal of Nuclear Medicine Technology September 1, 2018, 46 (3) 237-244; DOI: https://doi.org/10.2967/jnmt.118.209148
You have access
Imaging-Guided Use of Combined ¹⁷⁷Lu-DOTATATE and Capecitabine Therapy in Metastatic Mediastinal Paraganglioma
Abhiram G. Ashwathanarayana, Chinmoy K. Biswal, Ashwani Sood, Ashwin S. Parihar, Rakesh Kapoor and Bhagwant R. Mittal

Journal of Nuclear Medicine Technology December 1, 2017, 45 (4) 314-316; DOI: https://doi.org/10.2967/jnmt.117.197400
You have access
¹⁷⁷Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function
Rohit Ranade and Sandip Basu

Journal of Nuclear Medicine Technology June 1, 2016, 44 (2) 65-69; DOI: https://doi.org/10.2967/jnmt.115.168146
You have access
Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted ¹⁷⁷Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
Sandip Basu and Rohit Ranade

Journal of Nuclear Medicine Technology June 1, 2016, 44 (2) 85-87; DOI: https://doi.org/10.2967/jnmt.115.163527

Main menu

User menu

Search

177Lu-DOTATATE

Pages